BRPI0518302A2 - mÉtodo de formaÇço de imagens por rm - Google Patents

mÉtodo de formaÇço de imagens por rm

Info

Publication number
BRPI0518302A2
BRPI0518302A2 BRPI0518302-2A BRPI0518302A BRPI0518302A2 BR PI0518302 A2 BRPI0518302 A2 BR PI0518302A2 BR PI0518302 A BRPI0518302 A BR PI0518302A BR PI0518302 A2 BRPI0518302 A2 BR PI0518302A2
Authority
BR
Brazil
Prior art keywords
imaging method
imaging
myocardium
pyruvate
mri
Prior art date
Application number
BRPI0518302-2A
Other languages
English (en)
Inventor
Mathilde Lerche
Rene Zandt
Klaes Koppel Golman
Mikkel Thaning
Jan-Henrik Ardenkjaer-Larsen
Stefan Petersson
Original Assignee
Ge Healthcare As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare As filed Critical Ge Healthcare As
Publication of BRPI0518302A2 publication Critical patent/BRPI0518302A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48—NMR imaging systems
    • G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
    • G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
    • G01R33/5601—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Signal Processing (AREA)
  • General Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)

Abstract

MÉTODO DE FORMAÇçO DE IMAGENS POR RM. A presente invenção refere-se a um método para a produção de imagens cardíacas utilizando-se ^ 13^C-piruvato como agente de formação de imagens por RM, que permite a determinação da viabilidade de células no rmocárdio.
BRPI0518302-2A 2004-11-19 2005-11-18 mÉtodo de formaÇço de imagens por rm BRPI0518302A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO20045058 2004-11-19
PCT/NO2005/000434 WO2006054903A2 (en) 2004-11-19 2005-11-18 Method of cardiac imaging with the use of hyperpolarized 13 c-pyruvate

Publications (1)

Publication Number Publication Date
BRPI0518302A2 true BRPI0518302A2 (pt) 2008-11-11

Family

ID=36182402

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518302-2A BRPI0518302A2 (pt) 2004-11-19 2005-11-18 mÉtodo de formaÇço de imagens por rm

Country Status (13)

Country Link
US (1) US8980224B2 (pt)
EP (1) EP1824523B1 (pt)
JP (1) JP5456256B2 (pt)
KR (1) KR101249634B1 (pt)
CN (1) CN101102799B (pt)
AU (1) AU2005307194B2 (pt)
BR (1) BRPI0518302A2 (pt)
CA (1) CA2587795C (pt)
ES (1) ES2422558T3 (pt)
MX (1) MX2007006048A (pt)
PL (1) PL1824523T3 (pt)
RU (1) RU2391047C2 (pt)
WO (1) WO2006054903A2 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1962912T3 (pl) * 2005-12-16 2013-03-29 Ge Healthcare As Sposób wytwarzania hiperpolaryzowanych karboksylanów amin organicznych
US7202665B1 (en) * 2006-04-19 2007-04-10 Wisconsin Alumni Research Foundation Magnetic resonance spectroscopy of species with multiple peaks
US20080171893A1 (en) 2006-07-11 2008-07-17 Spectra Gases, Inc. Isotopically labeled alpha-keto acids and esters
CN101506679B (zh) * 2006-08-18 2013-03-06 通用电气医疗集团股份有限公司 细胞死亡的13c-mr成像或波谱分析
EP2051739A2 (en) * 2006-08-18 2009-04-29 GE Healthcare AS Imaging medium comprising lactate and hyperpolarised 13c-pyruvate
KR20140144312A (ko) 2006-08-30 2014-12-18 지이 헬스케어 에이에스 동적 핵 분극화 방법 및 이러한 방법에서 사용되는 화합물 및 조성물
WO2008063078A1 (en) * 2006-11-21 2008-05-29 Ge Healthcare As Method for managing patients with cancers
WO2008086534A1 (en) 2007-01-11 2008-07-17 Huntington Medical Research Institutes Imaging agents and methods of use thereof
US8483798B2 (en) * 2007-01-15 2013-07-09 General Electric Company System and method for metabolic MR imaging of a hyperpolarized agent
US8983570B2 (en) * 2007-03-27 2015-03-17 Cardiovascular Biotherapeutics, Inc. Therapeutic angiogenesis for treatment of the spine
US11224635B2 (en) 2007-03-27 2022-01-18 Venturis Thereuptics, Inc. Therapeutic angiogenesis for treatment of the spine and other tissues
US7470813B2 (en) 2007-03-30 2008-12-30 Ge Healthcare Limited Method for the production of pyruvic acid
CN105054933A (zh) * 2007-05-17 2015-11-18 通用电气公司 使用包含超极化13c-丙酮酸盐的成像介质使肿瘤分级的mr方法
GB0713074D0 (en) 2007-07-05 2007-08-15 Univ London A method of hyperpolarising a magnetic resonance agent
CN101970014A (zh) * 2007-07-26 2011-02-09 通用电气医疗集团英国有限公司 包含超极化的13c-乳酸盐的成像介质及其用途
US20110033387A1 (en) * 2007-09-07 2011-02-10 Ge Healthcare Limited Method of determination of pdh activity and imaging media for use in said method
EP2072061A1 (en) 2007-12-19 2009-06-24 GE Healthcare Limited Composition and method for generating a metabolic profile using 13C-MR detection
WO2009129265A1 (en) 2008-04-14 2009-10-22 Huntington Medical Research Institutes Methods and apparatus for pasadena hyperpolarization
US20110038802A1 (en) 2008-05-02 2011-02-17 Zhong-Min Hu Method of determining alanine transaminase (alt) activity by 13c-mr detection using hyperpolarised 13c-pyruvate
AU2010230330B2 (en) * 2009-04-02 2015-06-25 Ge Healthcare Limited Use of a magnetic resonance imaging medium comprising hyperpolarized 13C pyruvate for the detection of inflammation or infection
US8968703B2 (en) * 2009-09-10 2015-03-03 Ge Healthcare Limited 13C-MR detection using hyperpolarised 13C-fructose
EP2343568A1 (en) * 2009-12-30 2011-07-13 Koninklijke Philips Electronics N.V. Dynamic nuclear polarization apparatus with sample transport system
EP2539726B1 (en) * 2010-02-22 2020-05-13 Koninklijke Philips N.V. Rf antenna arrangement and method for multi nuclei mr image reconstruction involving parallel mri
WO2012145733A1 (en) 2011-04-22 2012-10-26 Vanderbilt University Para-hydrogen polarizer
US9381257B2 (en) * 2012-07-13 2016-07-05 Bracco Imaging S.P.A. Triarylmethyl radicals
US9874622B2 (en) 2013-09-27 2018-01-23 General Electric Company Hyperpolarized media transport vessel
KR101516634B1 (ko) * 2014-07-09 2015-05-06 연세대학교 산학협력단 13c-자기공명분광영상을 이용한 암 환자의 치료 예후를 예측하는 방법
RU2622983C1 (ru) * 2016-07-25 2017-06-21 федеральное государственное бюджетное образовательное учреждение высшего образования "Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации Способ интраоперационной визуализации ишемически-реперфузионного повреждения миокарда
WO2019159154A1 (en) * 2018-02-19 2019-08-22 Bruker France Sas Nuclear spin hyperpolarization in a porous matrix
US11350888B2 (en) * 2019-09-03 2022-06-07 Siemens Healthcare Gmbh Risk prediction for sudden cardiac death from image derived cardiac motion and structure features
WO2025137625A1 (en) * 2023-12-22 2025-06-26 The Board Of Regents Of The University Of Texas System Hyperpolarized 13c pyruvate mri and pet in single exam using pet-mr for ischemic heart disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597548A (en) * 1990-07-18 1997-01-28 Board Of Regents, The University Of Texas System 13 C Isotopomer analyses in intact tissue using (13 C) homonuclear decoupling
EP0951650B1 (en) * 1997-01-08 2003-12-10 Amersham Health AS Method of magnetic resonance imaging
US6278893B1 (en) * 1998-01-05 2001-08-21 Nycomed Imaging As Method of magnetic resonance imaging of a sample with ex vivo polarization of an MR imaging agent
US6958244B2 (en) * 2002-04-12 2005-10-25 Bruker Biospin Corp. Low-conductivity buffers for magnetic resonance measurements

Also Published As

Publication number Publication date
RU2007118383A (ru) 2008-12-27
PL1824523T3 (pl) 2013-12-31
WO2006054903A2 (en) 2006-05-26
WO2006054903A3 (en) 2007-03-15
KR101249634B1 (ko) 2013-04-01
US8980224B2 (en) 2015-03-17
CA2587795C (en) 2015-01-20
KR20070089171A (ko) 2007-08-30
MX2007006048A (es) 2007-07-25
RU2391047C2 (ru) 2010-06-10
US20090162287A1 (en) 2009-06-25
JP5456256B2 (ja) 2014-03-26
EP1824523B1 (en) 2013-05-01
ES2422558T3 (es) 2013-09-12
JP2008520335A (ja) 2008-06-19
EP1824523A2 (en) 2007-08-29
AU2005307194A1 (en) 2006-05-26
CN101102799A (zh) 2008-01-09
CN101102799B (zh) 2011-05-04
AU2005307194B2 (en) 2011-02-10
CA2587795A1 (en) 2006-05-26

Similar Documents

Publication Publication Date Title
BRPI0518302A2 (pt) mÉtodo de formaÇço de imagens por rm
UY31816A (es) Agente para el tratamiento y/o prevención de una enfemedad autoinmune y para la formación de células t reguladoras
BRPI0901516A2 (pt) reconstrução de imagem tri-dimensional usando ultra-som doppler
HK1212388A1 (en) Methods of tissue generation
NI201200038A (es) Conjugados de niacina y ácidos grasos y sus usos
UY32037A (es) Daa-piridina
ECSP13011139A (es) Anticuerpos contra la angiopoyetina 2 humana
BRPI0515684A (pt) formulações de cristais injetáveis ativas de longa duração de metabólitos de estradiol, e métodos de utilização das mesmas
MX2009000520A (es) Metodos para producir combustibles y solventes.
GB2459228A (en) Exosome-associated microrna as a diagnostic marker
EP3825419A3 (en) Diagnostic, prognostic and therapeutic uses of long noncoding rnas for heart disease and regenerative medicine
CY1117847T1 (el) Φαρμακευτικο σκευασμα που περιλαμβανει ενα ή περισσοτερους εστερες φουμαρικου οξεος σε μητρα διαβρωσης
GT200600112A (es) Composiciiones de tigeciclina y metodos de preparacion
MX346145B (es) Composición de sistema de suministro de arnsi in vivo basado en péptidos.
WO2006138669A3 (en) Life-like anatomic feature for testing injection of soft tissue fillers
BR112015001414A2 (pt) composição antideriva
BRPI0510487A (pt) agentes de contraste para estudo por imagens de perfusão do miocárdio
ES2560676T3 (es) Combinación farmacéutica para el tratamiento del dolor
BR112012029271A2 (pt) fungo isolado, método para produzir e kit para fabricar pelo menos um composto selecionado do grupo que consite de 1, 8-cineol, 1-metil-1,4-cicloexadieno, e (+) -a-metileno-a-fenchocanforona, molécula de ácido nucleico isolada de um fungo,e, método para gerar cepas mutantes de um fungo.
BR112012014621A2 (pt) processo para a preparação de compostos de quelato
ATE551677T1 (de) Durch 3d-2d-adaptives formmodel unterstützte bewegungskompensierte rekonstruktion
BR112014009223A8 (pt) método para o diagnóstico da doença de niemann-pick
NI200700299A (es) Composicion de liberación modificada de al menos una forma de venlafaxina
BR112017027304A2 (pt) método para o diagnóstico de doença de farber
CO6300936A2 (es) Procedimiento para revertir la remodelacion cardiaca electrofisiologica de un animal con cardiopatia usando beta-adrenoceptores

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: A61K 49/06

Ipc: A61K 49/06 (2006.01), G01R 33/00 (2006.01)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]